+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Intranasal Drug & Vaccine Delivery Market - Global Forecast 2026-2032- Product Image
Intranasal Drug & Vaccine Delivery Market - Global Forecast 2026-2032- Product Image
Sale

Intranasal Drug & Vaccine Delivery Market - Global Forecast 2026-2032

  • Report

  • 192 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5533387
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Intranasal Drug & Vaccine Delivery Market is projected to reach USD 55.44 Billion in 2026. It is expected to continue growing at a CAGR of 6.14%, reaching USD 79.61 Billion by 2032.

Intranasal drug and vaccine delivery is moving from a niche route of administration to a strategic platform for acute rescue medicines, central nervous system therapies, respiratory immunization, and patient-centric chronic care. The route is commercially validated by products such as naloxone nasal spray, which the U.S. FDA approved for over-the-counter use in 2023, and prescription intranasal rescue therapies including midazolam and diazepam for seizure clusters.

For biopharma and vaccine developers, the opportunity is anchored in rapid systemic absorption through the highly vascular nasal mucosa, avoidance of hepatic first-pass metabolism, noninvasive administration, and the potential induction of local mucosal immunity in the upper respiratory tract. These advantages support differentiated pipelines in nasal vaccines, nose-to-brain delivery, metered-dose sprays, and dry powder nasal formulations, while also improving usability in emergency, pediatric, geriatric, and decentralized-care settings.

Transformative Shifts Reshaping the Intranasal Delivery Landscape

The intranasal drug and vaccine delivery landscape is being reshaped by three verified shifts: emergency-use adoption, combination-product sophistication, and renewed interest in mucosal immunization. Over-the-counter naloxone expanded the public-health role of nasal delivery, while FDA-approved intranasal esketamine, midazolam, and diazepam demonstrated that nasal platforms can support regulated, high-value therapeutics requiring precise dosing, human-factor validation, and post-market safety monitoring.

Vaccine developers are also reassessing nasal delivery after the COVID-19 pandemic exposed limitations in injection-only immunization strategies, particularly for blocking respiratory transmission at mucosal surfaces. FluMist remains an established intranasal influenza vaccine option for eligible people, while countries including India and China advanced mucosal COVID-19 vaccine approaches, reinforcing global interest in respiratory-tract immune protection, needle-free delivery, and scalable immunization formats.

Cumulative Impact of Artificial Intelligence on Intranasal Platforms

Artificial intelligence is becoming cumulative rather than experimental in intranasal drug and vaccine development. AI-enabled formulation screening can help model particle size, viscosity, excipient compatibility, spray plume geometry, droplet distribution, deposition behavior, and nasal residence time, all of which influence intranasal bioavailability, dose reproducibility, and patient outcomes.

For biologics and nasal vaccines, machine learning can support antigen selection, adjuvant optimization, stability prediction, immune-response profiling, and clinical trial enrichment. In commercialization, AI improves pharmacovigilance signal detection, supply planning, patient education, and adherence support for products such as rescue nasal sprays, where real-world usability, rapid onset, and speed of administration are central to clinical value.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

North America leads in regulatory precedents and commercialization, supported by U.S. FDA approvals for over-the-counter naloxone nasal spray, intranasal seizure rescue medicines, and esketamine administered under a Risk Evaluation and Mitigation Strategy. Canada contributes mature public-health procurement, vaccination infrastructure, and clinical adoption of patient-friendly delivery systems, while Mexico adds access potential through expanding pharmaceutical distribution and cross-border public-health relevance.

Europe benefits from established European Medicines Agency pathways, strong pharmacovigilance systems, sophisticated clinical research networks, and the European Union’s focus on preparedness and cross-border health security. The United Kingdom, Germany, France, Italy, and Spain provide important clinical, regulatory, and payer environments for intranasal therapeutics, while broader regional demand is influenced by vaccination policy, respiratory-disease prevention, and acceptance of self-administered medicines.

Asia-Pacific is expanding through China, India, Japan, South Korea, and Australia, where vaccine capacity, respiratory-disease burden, biologics manufacturing, and local innovation policy are accelerating interest in nasal vaccines, nasal sprays, and advanced delivery devices. India and China have already demonstrated national activity in mucosal COVID-19 vaccine development, while Japan, South Korea, and Australia reinforce the region’s role through high regulatory standards, device engineering, and advanced healthcare adoption.

Latin America, the Middle East, and Africa are adoption markets with strong public-health relevance, especially for needle-free vaccination, overdose response, pediatric use, and decentralized care. Brazil anchors Latin American demand through public immunization infrastructure, while GCC health systems in the Middle East are investing in emergency readiness, preventive care, and specialty medicine access. Across Africa, intranasal platforms are relevant where simplified administration, cold-chain resilience, and community-based delivery can improve reach.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7 & NATO

The European Union and G7 provide the strongest alignment for advanced regulatory science, pandemic preparedness, clinical evidence standards, and reimbursement evaluation, making them influential for nasal biologics, vaccines, rescue medicines, and central nervous system therapies. NATO countries add defense-health relevance where fast administration, field readiness, stockpiling, and training simplicity are priorities for medical countermeasures and emergency-response products.

BRICS markets offer scale, manufacturing capacity, public-health demand, and rising domestic innovation, particularly across China, India, and Brazil, where vaccine production, respiratory-disease burden, and government-backed health programs support intranasal drug and vaccine delivery. ASEAN countries create growth opportunities through large pediatric populations, expanding immunization programs, urban healthcare modernization, and regional regulatory harmonization efforts. GCC health systems are investing in advanced hospitals, preventive care, emergency-response readiness, and specialty access, supporting premium adoption of innovative intranasal products where clinical differentiation and convenience are well demonstrated.

Key Country Insights Across Major Intranasal Delivery Markets

The United States is the benchmark market for intranasal drug delivery because of FDA precedents in naloxone, esketamine, midazolam, and diazepam nasal products, as well as mature frameworks for combination products, human-factor testing, labeling, and post-market surveillance. Canada supports adoption through established public-health systems and vaccination infrastructure, while Mexico adds North American access potential through expanding healthcare coverage, pharmaceutical distribution, and demand for practical, noninvasive therapies.

Brazil anchors Latin American relevance through public immunization infrastructure, respiratory-health priorities, and growing pharmaceutical capabilities. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong clinical trial networks, advanced specialist care, and established reimbursement review processes, although payer scrutiny requires clear evidence for onset of action, adherence, safety, and therapeutic differentiation. Russia remains relevant through domestic vaccine capacity and public-sector interest in locally produced immunization technologies.

China and India are strategic for intranasal vaccine development, manufacturing scale, respiratory-disease prevention, and cost-efficient delivery formats, with both countries having advanced mucosal COVID-19 vaccine approaches during the pandemic era. Japan, Australia, and South Korea contribute high regulatory standards, sophisticated device adoption, strong clinical capabilities, and demand for patient-friendly therapies, making them important markets for validated nasal sprays, dry powder systems, and next-generation intranasal biologics.

Actionable Recommendations for Intranasal Delivery Leaders

Industry leaders should prioritize indication-device fit before scale-up, because nasal delivery performance depends on dose volume, plume geometry, droplet or particle size, viscosity, mucociliary clearance, nasal physiology, and user technique. Early human-factor studies are essential for rescue medicines and self-administered vaccines, particularly when products are intended for caregivers, patients under stress, pediatric populations, or community-based administration.

Biopharma teams should build evidence packages around bioavailability, onset of action, mucosal immune markers where relevant, immunogenicity, stability, dose reproducibility, device reliability, and real-world adherence. Partnerships with device engineers, contract development and manufacturing organizations, AI formulation platforms, clinical networks, and public-health agencies can shorten development timelines while improving regulatory confidence, product usability, and market access readiness.

Research Methodology

This executive summary is based on triangulated secondary research from regulatory databases, public-health agencies, product labels, clinical-trial registries, peer-reviewed literature, vaccine policy references, and publicly available health authority documentation. Priority was given to verified approvals, guidance, documented product categories, and established clinical use cases rather than unsupported market-size estimates.

The methodology evaluates intranasal drug delivery and nasal vaccine delivery by therapeutic area, dosage form, device type, regulatory pathway, regional adoption, public-health relevance, and commercial readiness. Findings were validated through cross-comparison of FDA, EMA, CDC, WHO, and national health authority references where applicable, with emphasis on traceable evidence related to safety, efficacy, usability, mucosal immunology, and combination-product performance.

Conclusion

Intranasal drug and vaccine delivery is entering a more competitive and evidence-driven phase. Proven use cases in overdose reversal, seizure rescue, depression treatment, and influenza vaccination have established the route’s credibility, while ongoing work in mucosal vaccines, dry powder delivery, biologics, and nose-to-brain delivery expands its strategic importance.

The strongest opportunities will favor developers that combine rigorous formulation science, validated delivery devices, AI-enabled optimization, human-factor evidence, and clear regulatory documentation. As health systems demand faster, needle-free, scalable, and patient-friendly interventions, intranasal platforms are positioned for sustained relevance across emergency care, immunization, neurology, psychiatry, and respiratory health.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Intranasal Drug & Vaccine Delivery Market, by Drug Type
7.1. Introduction
7.2. Analgesics
7.2.1. Non-opioids
7.2.2. Opioids
7.3. Antihistamines
7.4. Steroids
7.5. Vaccines
7.5.1. Inactivated Vaccines
7.5.2. Live Attenuated Vaccines
7.5.3. mRNA-based Vaccine
8. Intranasal Drug & Vaccine Delivery Market, by Formulation Type
8.1. Introduction
8.2. Gel Formulations
8.3. Liquid Formulations
8.4. Powder Formulations
9. Intranasal Drug & Vaccine Delivery Market, by Device Type
9.1. Introduction
9.2. Atomizer
9.3. Nasal Dropper
9.4. Nasal Spray
10. Intranasal Drug & Vaccine Delivery Market, by Dosage
10.1. Introduction
10.2. Multi-dose
10.3. Unit-dose
11. Intranasal Drug & Vaccine Delivery Market, by Application
11.1. Introduction
11.2. Allergy Treatment
11.3. Hormone Replacement
11.4. Neurological Conditions
11.5. Pain Management
11.6. Psychiatric Disorders
11.7. Therapeutic Drug Delivery
12. Intranasal Drug & Vaccine Delivery Market, by End-User
12.1. Introduction
12.2. Homecare
12.3. Hospitals & Clinics
12.4. Research & Academic Institution
13. Intranasal Drug & Vaccine Delivery Market, by Region
13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa
14. Intranasal Drug & Vaccine Delivery Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Intranasal Drug & Vaccine Delivery Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Altimmune, Inc.
17.2. AptarGroup, Inc.
17.3. AstraZeneca PLC
17.4. Bausch Health Companies Inc.
17.5. Bayer AG
17.6. Becton, Dickinson, and Company
17.7. Bharat Biotech Ltd.
17.8. Boehringer Ingelheim International GmbH.
17.9. Catalent, Inc
17.10. DCA Design International Limited
17.11. Emergent BioSolutions Inc.
17.12. GlaxoSmithKline PLC
17.13. Hovione Limited
17.14. Impel Pharmaceuticals LLC.
17.15. Indivior PLC
17.16. Intersect ENT by Medtronic plc
17.17. Intertek Group PLC
17.18. Johnson & Johnson Services, Inc.
17.19. Kindeva Drug Delivery L.P.
17.20. Merck & Co., Inc.
17.21. Neurelis, Inc.
17.22. Novartis AG
17.23. OptiNose, Inc.
17.24. Pfizer Inc.
17.25. Recipharm AB.
17.26. Sanofi S.A.
17.27. Teleflex Incorporated
17.28. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ANALGESICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ANALGESICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ANALGESICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL NON-OPIOIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL NON-OPIOIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL NON-OPIOIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL ANTIHISTAMINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL ANTIHISTAMINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL ANTIHISTAMINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL STEROIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL STEROIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL STEROIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL LIVE ATTENUATED VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL LIVE ATTENUATED VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL LIVE ATTENUATED VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL MRNA-BASED VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL MRNA-BASED VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL MRNA-BASED VACCINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL GEL FORMULATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL GEL FORMULATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL GEL FORMULATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL LIQUID FORMULATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL LIQUID FORMULATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL LIQUID FORMULATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL POWDER FORMULATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL POWDER FORMULATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL POWDER FORMULATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL ATOMIZER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ATOMIZER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ATOMIZER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL NASAL DROPPER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL NASAL DROPPER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL NASAL DROPPER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL NASAL SPRAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL NASAL SPRAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL NASAL SPRAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL MULTI-DOSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL MULTI-DOSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL MULTI-DOSE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL UNIT-DOSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL UNIT-DOSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL UNIT-DOSE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ALLERGY TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL HORMONE REPLACEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL HORMONE REPLACEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL HORMONE REPLACEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL NEUROLOGICAL CONDITIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL NEUROLOGICAL CONDITIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL NEUROLOGICAL CONDITIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL THERAPEUTIC DRUG DELIVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL THERAPEUTIC DRUG DELIVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL THERAPEUTIC DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL RESEARCH & ACADEMIC INSTITUTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL RESEARCH & ACADEMIC INSTITUTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL RESEARCH & ACADEMIC INSTITUTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 97. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 99. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 100. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 101. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 106. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 108. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 109. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 110. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 111. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 112. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 115. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 117. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 118. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 119. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 120. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 121. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 122. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 123. EUROPE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 124. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 126. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 127. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 128. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 129. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 130. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 131. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 132. MIDDLE EAST INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 133. AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 135. AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 136. AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 137. AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 138. AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 139. AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 140. AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 141. AFRICA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 143. ASEAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. ASEAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 145. ASEAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 146. ASEAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 147. ASEAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 148. ASEAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 149. ASEAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 150. ASEAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 151. ASEAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 152. GCC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 153. GCC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 154. GCC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 155. GCC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 156. GCC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 157. GCC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 158. GCC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 159. GCC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 160. GCC INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 170. BRICS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 171. BRICS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 172. BRICS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 173. BRICS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 174. BRICS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 175. BRICS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 176. BRICS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 177. BRICS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 178. BRICS INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 179. G7 INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 180. G7 INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 181. G7 INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 182. G7 INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 183. G7 INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 184. G7 INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 185. G7 INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 186. G7 INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 187. G7 INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 188. NATO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 189. NATO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 190. NATO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 191. NATO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 192. NATO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 193. NATO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 194. NATO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 195. NATO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 196. NATO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 197. GLOBAL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 198. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 199. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 200. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 201. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 202. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 203. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 204. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 205. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 206. UNITED STATES INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 207. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 208. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 209. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 210. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 211. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 212. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 213. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 214. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 215. CANADA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 216. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 217. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 218. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 219. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 220. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 221. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 222. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 223. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 224. MEXICO INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 225. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 226. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 227. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 228. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 229. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 230. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 231. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 232. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 233. BRAZIL INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 234. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 235. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 236. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 237. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 238. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 239. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 240. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 241. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 242. UNITED KINGDOM INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 243. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 244. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 245. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 246. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 247. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 248. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 249. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 250. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 251. GERMANY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 252. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 253. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 254. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 255. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 256. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 257. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 258. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 259. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 260. FRANCE INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 261. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 262. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 263. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 264. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 265. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 266. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 267. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 268. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 269. RUSSIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 270. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 271. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 272. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 273. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 274. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 275. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 276. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 277. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 278. ITALY INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 279. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 280. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 281. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 282. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 283. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 284. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 285. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 286. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 287. SPAIN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 288. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 289. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 290. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 291. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 292. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 293. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 294. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 295. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 296. CHINA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 297. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 298. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 299. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 300. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 301. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 302. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 303. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 304. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 305. INDIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 306. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 307. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 308. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 309. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 310. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 311. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 312. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 313. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 314. JAPAN INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 315. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 316. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 317. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 318. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 319. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 320. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 321. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOSAGE, 2017-2032 (USD MILLION)
TABLE 322. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 323. AUSTRALIA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY END-USER, 2017-2032 (USD MILLION)
TABLE 324. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 325. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 326. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY ANALGESICS, 2017-2032 (USD MILLION)
TABLE 327. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 328. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 329. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 330. SOUTH KOREA INTRANASAL DRUG & VACCINE DELIVERY MARKET SIZE, BY DOS

Companies Mentioned

  • Altimmune, Inc.
  • AptarGroup, Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Becton, Dickinson, and Company
  • Bharat Biotech Ltd.
  • Boehringer Ingelheim International GmbH.
  • Catalent, Inc
  • DCA Design International Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline PLC
  • Hovione Limited
  • Impel Pharmaceuticals LLC.
  • Indivior PLC
  • Intersect ENT by Medtronic plc
  • Intertek Group PLC
  • Johnson & Johnson Services, Inc.
  • Kindeva Drug Delivery L.P.
  • Merck & Co., Inc.
  • Neurelis, Inc.
  • Novartis AG
  • OptiNose, Inc.
  • Pfizer Inc.
  • Recipharm AB.
  • Sanofi S.A.
  • Teleflex Incorporated
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages192
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 55.44 Billion
Forecasted Market Value ( USD ) by 2032 $ 79.61 Billion
Compound Annual Growth Rate6.1%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Vaccine Delivery Devices Market - Global Forecast 2026-2032 - Product Image

Vaccine Delivery Devices Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Vaccine Delivery Devices - Global Strategic Business Report - Product Image

Vaccine Delivery Devices - Global Strategic Business Report

  • Report
  • 282 Pages
  • Global
From
Vaccine Delivery Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Vaccine Delivery Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 180 Pages
  • Global
From
Vaccine Delivery Devices Market Report 2026 - Product Image

Vaccine Delivery Devices Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Vaccine Delivery Device Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Vaccine Delivery Device Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.